

Jacob M Van Laar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/260335/publications.pdf>

Version: 2024-02-01

166
papers

6,752
citations

109264

35
h-index

69214

77
g-index

168
all docs

168
docs citations

168
times ranked

6941
citing authors

#	ARTICLE	IF	CITATIONS
1	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
2	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	3.8	566
3	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 39-52.	0.5	506
4	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	6.3	505
5	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	5.2	348
6	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.5	236
7	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	2.5	231
8	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
9	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
10	Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 167-178.	3.5	130
11	Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. <i>RMD Open</i> , 2019, 5, e001035.	1.8	113
12	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy. <i>Arthritis and Rheumatism</i> , 2001, 44, 754-760.	6.7	110
13	Haematopoietic stem cell transplantation for autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2017, 13, 244-256.	3.5	108
14	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
15	Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systematic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. <i>RMD Open</i> , 2019, 5, e001041.	1.8	104
16	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
17	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	1.8	91
18	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.5	83

#	ARTICLE	IF	CITATIONS
19	Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. <i>Rheumatology</i> , 2016, 55, 826-839.	0.9	81
20	Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1402-1403.	0.5	80
21	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	6.3	78
22	MiR-29a Reduces TIMP-1 Production by Dermal Fibroblasts via Targeting TGF- β 2 Activated Kinase 1 Binding Protein 1, Implications for Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e115596.	1.1	75
23	Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. <i>Rheumatology</i> , 2021, 60, 3778-3788.	0.9	74
24	Association of MicroRNA-18 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1891-1902.	2.9	67
25	OUP accepted manuscript. <i>Rheumatology</i> , 2018, 57, 1135-1144.	0.9	60
26	Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 63-69.	0.6	54
27	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
28	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
29	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50
30	Microbial Dysbiosis in Common Variable Immune Deficiencies: Evidence, Causes, and Consequences. <i>Trends in Immunology</i> , 2017, 38, 206-216.	2.9	47
31	Histone Demethylation and Toll-like Receptor α -Dependent Cross-Talk in Monocytes Promotes Transdifferentiation of Fibroblasts in Systemic Sclerosis Via FRA-2. <i>Arthritis and Rheumatology</i> , 2016, 68, 1493-1504.	2.9	43
32	Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF- α Inhibitors in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0163087.	1.1	43
33	Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001512.	1.8	42
34	Differentiation Potential of CD14+ Monocytes into Myofibroblasts in Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2012, 7, e33508.	1.1	41
35	Intense Immunosuppression and Stem-Cell Transplantation for Patients with Severe Rheumatic Autoimmune Disease: A Review. <i>Cancer Control</i> , 2003, 10, 57-65.	0.7	38
36	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	1.8	38

#	ARTICLE	IF	CITATIONS
37	Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 2126-2133.	0.9	35
38	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
39	Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000789.	1.8	34
40	Emerging role of epigenetics in systemic sclerosis pathogenesis. <i>Genes and Immunity</i> , 2014, 15, 433-439.	2.2	33
41	Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. <i>Journal of Immunology Research</i> , 2017, 2017, 1-5.	0.9	33
42	Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1261-1267.	0.5	32
43	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1084-1089.	0.5	32
44	Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. <i>PLoS ONE</i> , 2018, 13, e0201527.	1.1	29
45	Knee Joint Distraction Compared to Total Knee Arthroplasty for Treatment of End Stage Osteoarthritis: Simulating Long-Term Outcomes and Cost-Effectiveness. <i>PLoS ONE</i> , 2016, 11, e0155524.	1.1	28
46	Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1432-1435.	0.5	28
47	Stem cell transplantation in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 719-725.	2.0	25
48	Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. <i>Arthritis Research and Therapy</i> , 2018, 20, 230.	1.6	25
49	Stem cell transplantation and mesenchymal cells to treat autoimmune diseases. <i>Presse Medicale</i> , 2016, 45, e159-e169.	0.8	23
50	Cellular Therapies in Systemic Sclerosis: Recent Progress. <i>Current Rheumatology Reports</i> , 2016, 18, 12.	2.1	23
51	Heat Shock Proteins Can Be Surrogate Autoantigens for Induction of Antigen Specific Therapeutic Tolerance in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 279.	2.2	22
52	Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1146-1149.	1.3	21
53	A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol. <i>BMJ Open</i> , 2018, 8, e020479.	0.8	21
54	Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. <i>Respiratory Medicine</i> , 2021, 187, 106579.	1.3	21

#	ARTICLE	IF	CITATIONS
55	Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. <i>Rheumatology</i> , 2021, 60, 4681-4690.	0.9	20
56	Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. <i>PLoS ONE</i> , 2017, 12, e0188810.	1.1	20
57	A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1788-1798.	1.9	19
58	Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. <i>Rheumatology</i> , 2022, 61, 3552-3566.	0.9	19
59	Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis. <i>Clinical Rheumatology</i> , 2018, 37, 1879-1884.	1.0	18
60	Targeting of tolerogenic dendritic cells towards heat shock proteins: a novel therapeutic strategy for autoimmune diseases?. <i>Immunology</i> , 2018, 153, 51-59.	2.0	18
61	Scleroderma Lung. <i>Drugs</i> , 2007, 67, 985-996.	4.9	17
62	Optical spectral transmission to assess inflammation in hand and wrist joints of rheumatoid arthritis patients. <i>Rheumatology</i> , 2018, 57, 865-872.	0.9	17
63	Automated joint space width quantification of hand and wrist joints: a proof of concept study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S34-S39.	0.4	17
64	Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. <i>Arthritis Research and Therapy</i> , 2017, 19, 170.	1.6	16
65	Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1333-1338.	0.5	15
66	Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	0.9	14
67	Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon. <i>Arthritis Research and Therapy</i> , 2021, 23, 184.	1.6	14
68	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	0.9	13
69	Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update. <i>Frontiers in Immunology</i> , 2018, 9, 767.	2.2	13
70	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective. <i>Rheumatology</i> , 2020, 59, 2052-2061.	0.9	13
71	Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. <i>Clinical Immunology</i> , 2020, 214, 108392.	1.4	13
72	High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 233-245.	0.7	12

#	ARTICLE	IF	CITATIONS
73	Contribution of the Subjective Components of the Disease Activity Score to the Response to Biologic Treatment in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 923-928.	1.5	12
74	Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. <i>Rheumatology</i> , 2018, 57, 309-317.	0.9	12
75	Autologous hematopoietic stem cell transplantation in systemic sclerosis: A reset to tolerance?. <i>Immunology Letters</i> , 2018, 195, 88-96.	1.1	12
76	Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1485.	2.2	12
77	Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001511.	1.8	12
78	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
79	Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. <i>Rheumatology</i> , 2022, 61, 4232-4244.	0.9	12
80	How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?. <i>Rheumatology</i> , 2020, 59, 1226-1232.	0.9	11
81	Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101485.	1.4	11
82	Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use. <i>Journal of Rheumatology</i> , 2021, 48, 1504-1507.	1.0	11
83	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	0.8	11
84	The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. <i>Arthritis Research and Therapy</i> , 2018, 20, 256.	1.6	10
85	Text Mining of Electronic Health Records Can Accurately Identify and Characterize Patients With Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 65-71.	0.9	10
86	Building a Tailored, Patient-Guided, Web-Based Self-Management Intervention "ReumaUitgedaagd!"™ for Adults With a Rheumatic Disease: Results of a Usability Study and Design for a Randomized Control Trail. <i>JMIR Research Protocols</i> , 2016, 5, e113.	0.5	10
87	Rheumatoid vasculitis presenting as appendicitis. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 736-8.	0.4	10
88	Measurement of antinuclear antibodies and their fine specificities: time for a change in strategy?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 462-470.	0.4	10
89	The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation. <i>Clinical and Experimental Immunology</i> , 2020, 201, 34-39.	1.1	9
90	Predicting Flare Probability in Rheumatoid Arthritis using Machine Learning Methods. , 2018, , .		9

#	ARTICLE	IF	CITATIONS
91	The immunopathology of systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 439-441.	2.8	8
92	Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review. <i>Joint Bone Spine</i> , 2020, 87, 13-23.	0.8	8
93	Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110351.	1.2	8
94	Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. <i>Rheumatology</i> , 2021, 60, 5105-5116.	0.9	8
95	Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience. <i>Journal of rheumatology Supplement, The</i> , 2001, 64, 25-7.	2.2	8
96	Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review. <i>Current Rheumatology Reports</i> , 2019, 21, 24.	2.1	7
97	Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 495-503.	1.0	7
98	Proteomics to predict the response to tumour necrosis factor- α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 12-21.	0.6	6
99	Targeting the TLR4-MD2 axis in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 564-566.	3.5	6
100	Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology?. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 399-416.	0.8	6
101	Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 142-144.	0.5	6
102	Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate. <i>Rheumatology</i> , 2020, 59, 2325-2333.	0.9	6
103	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. <i>RMD Open</i> , 2020, 6, e001344.	1.8	6
104	Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 460-463.	0.5	6
105	Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD). <i>Clinical and Experimental Immunology</i> , 2021, 203, 160-173.	1.1	6
106	Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1948-1956.	0.9	6
107	Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial. <i>Journal of Controlled Release</i> , 2022, 341, 548-554.	4.8	6
108	Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment?. <i>Rheumatology</i> , 2016, 55, 94-102.	0.9	5

#	ARTICLE	IF	CITATIONS
109	Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. <i>Rheumatology</i> , 2017, 56, 2179-2189.	0.9	5
110	RNA sequencing to predict response to TNF- α inhibitors reveals possible mechanism for nonresponse in smokers. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 623-633.	1.3	5
111	Clinical Practice Audit on the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Netherlands. <i>Kidney International Reports</i> , 2021, 6, 2671-2678.	0.4	5
112	Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 221-228.	0.4	5
113	Effectiveness of Tocilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial. <i>Trials</i> , 2020, 21, 313.	0.7	4
114	Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 199-205.	1.0	4
115	Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 976-983.	0.4	4
116	Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 66-70.	0.4	4
117	Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosis-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1803.	3.8	3
118	Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis. , 2019, , .		3
119	Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis. <i>Trials</i> , 2019, 20, 226.	0.7	3
120	SAT0296-FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
121	Development and Validation of Rheumatoid Arthritis Disease Activity Indices Including <scp>HandScan</scp> (Optical Spectral Transmission) Scores. <i>Arthritis Care and Research</i> , 2022, 74, 1493-1499.	1.5	3
122	SAT0052-THERAPEUTIC STRATEGIES IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 957-957.	0.5	3
123	Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies. <i>Lupus Science and Medicine</i> , 2021, 8, e000531.	1.1	3
124	Cardiovascular risk in patients with new gout diagnosis: is monosodium urate volume at ankles and feet on dual-energy computed tomography associated with previous cardiovascular events?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 763-766.	0.4	3
125	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3
126	Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2022, 238, 1108-1119.	0.9	3

#	ARTICLE	IF	CITATIONS
127	Do high levels of IgA rheumatoid factor indicate a poor response to treatment with TNF inhibitors in patients with RA?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 544-545.	3.2	2
128	Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000148.	1.8	2
129	Second autologous haematopoietic stem cell transplantation in systemic sclerosisâ€”a case report. <i>Rheumatology</i> , 2019, 58, 1305-1307.	0.9	2
130	From â€œbeing at warâ€”to â€œgetting back on your feetâ€”. A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 202-209.	1.0	2
131	Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab004.	0.3	2
132	Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report. <i>Rheumatology</i> , 2021, 60, e326-e328.	0.9	2
133	Response to: â€”Correspondence on â€”EULAR definition of difficult-to-treat rheumatoid arthritisâ€”â€” by Novella-Navarro<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e56-e56.	0.5	2
134	NT-proBNP and sRAGE levels in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 243-249.	0.6	2
135	Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	2
136	Immunology and systemic sclerosis - Editorial. <i>Immunology Letters</i> , 2018, 195, 1.	1.1	1
137	B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset. <i>Clinical and Experimental Immunology</i> , 2020, 201, 231-232.	1.1	1
138	Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 239719832110433.	1.0	1
139	SAT0169â€”No evidence that concomitant glucocorticoid therapy affects efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trials. , 2018, , .		1
140	FR10047â€”STRATEGIES REGARDING GOAL SETTING AND SELF-MANAGEMENT IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 599.2-599.	0.5	1
141	Economic evaluation of a tight-control treatment strategy using an imaging device (handscan) for monitoring joint inflammation in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 831-8.	0.4	1
142	Microarray analysis of autoantibodies can identify future Systemic Lupus Erythematosus patients. <i>Human Immunology</i> , 2022, 83, 509-514.	1.2	1
143	Tweaking Microtubules to Treat Scleroderma. <i>PLoS Medicine</i> , 2005, 2, e415.	3.9	0
144	Antibodies against citrullinated proteins: which test is best?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 652-653.	3.2	0

#	ARTICLE	IF	CITATIONS
145	Concepts of pathogenesis and emerging treatments for inflammatory arthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 537-538.	1.4	0
146	089â€¦Co-Morbidities after Daily Concomitant Treatment with 10 Mg Prednisone or Placebo in the 2 Year Computer-Assisted Management in Early Rheumatoid Arthritis Trial II. Rheumatology, 0, , .	0.9	0
147	OP0310â€¦Pregnancy outcome in women with systemic lupus erythematosus, a multicenter cohort-study. , 2017, , .		0
148	FRI0664â€¦Influence of joint pathology on optical spectral transmission imaging, assessing inflammation in hand and wrist joints of rheumatoid arthritis patients. , 2017, , .		0
149	AB1150â€¦The european reference network on rare and complex connective tissue and musculoskeletal diseases: ern reconnet. , 2018, , .		0
150	THU0119â€¦Smoking is negatively associated with clinical response to concomitant prednisone use in early rheumatoid arthritis. , 2018, , .		0
151	SAT0259â€¦PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
152	THU0198â€¦EFFECTIVENESS OF REMISSION-INDUCTION STRATEGIES FOR EARLY RHEUMATOID ARTHRITIS (RA): A SYSTEMATIC LITERATURE REVIEW. , 2019, , .		0
153	FRI0135â€¦INTRAVENOUS PEGYLATED LIPOSOMAL PREDNISOLONE SODIUM PHOSPHATE MORE EFFECTIVE THAN INTRAMUSCULAR INJECTION OF METHYLPREDNISOLONE ACETATE IN TREATING RA PATIENTS WHO ARE EXPERIENCING A FLARE: A PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED, MULTI-CENTER STUDY. , 2019, , .		0
154	AB0276â€¦IS PREDICTION OF CLINICAL RESPONSE TO METHOTREXATE IN INDIVIDUAL RHEUMATOID ARTHRITIS PATIENTS POSSIBLE? RESULTS OF A SYSTEMATIC LITERATURE REVIEW. , 2019, , .		0
155	OP0050â€¦ADDITIVE VALUE AND DIAGNOSTIC ACCURACY OF DUAL-ENERGY CT FOR THE DIAGNOSIS OF GOUT: A PROSPECTIVE STUDY IN SUBJECTS WITH UNCLASSIFIED MONO OR OLIGOARTHRITIS. , 2019, , .		0
156	AB0812â€¦BIOMARKERS FOR CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE: A PILOT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1430.1-1431.	0.5	0
157	POS1419â€¦PREDICTIVE FACTORS FOR PULMONARY PROGRESSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASE AND INTERSTITIAL LUNG DISEASE. Annals of the Rheumatic Diseases, 2021, 80, 993.1-993.	0.5	0
158	AB0914-PAREâ€¦INFORMATION PREFERENCES ABOUT TREATMENT OPTIONS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A DELPHI CONSENSUS STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1478.3-1479.	0.5	0
159	AB0884-HPRâ€¦PERSONALISED TREATMENT GOALS IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE. Annals of the Rheumatic Diseases, 2021, 80, 1465.1-1466.	0.5	0
160	POS0089â€¦AZD9567 VERSUS PREDNISOLONE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP EFFICACY AND SAFETY STUDY. Annals of the Rheumatic Diseases, 2021, 80, 253-254.	0.5	0
161	FRI0026â€¦U-act-early trial 3 years follow-up. the longer effectiveness of treat-to-target strategies in early ra with tocilizumab, methotrexate, or their combination. , 2018, , .		0
162	Cardiovascular risk in patients with new gout: should we reclassify the risk?. Clinical and Experimental Rheumatology, 2020, 38, 533-535.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Classification of rheumatoid arthritis into active or inactive with a modified Disease Activity score, for future use as a treat-to-target tool, with a HandScan score replacing joint counts. Clinical and Experimental Rheumatology, 0, , .	0.4	0
164	Classification of rheumatoid arthritis into active or inactive with a modified Disease Activity score, for future use as a treat-to-target tool, with a HandScan score replacing joint counts.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
165	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
166	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0